GSK(US:GSK) Zheng Quan Ri Bao·2026-02-11 05:40Core Viewpoint - GlaxoSmithKline (GSK) has announced that the China National Medical Products Administration (NMPA) has accepted its application for the marketing of a recombinant respiratory syncytial virus (RSV) vaccine, aimed at preventing lower respiratory tract diseases caused by RSV in adults aged 60 and above [1] Group 1: Vaccine Approval and Market Potential - The RSV vaccine, if approved, will be the first in China to help adults aged 60 and above prevent the severe consequences of RSV [1] - The vaccine has already been approved in over 65 countries for the prevention of lower respiratory tract diseases caused by RSV in the same age group [1] Group 2: Disease Impact and Statistics - RSV is a common and contagious virus that can lead to lung and respiratory infections, affecting approximately 64 million people globally each year [1] - In China, over 6 million individuals aged 60 and above are affected by RSV annually, resulting in more than 350,000 related hospitalizations [1]